CZEN 001
Alternative Names: CZEN-001Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Zengen
- Class Melanocyte-stimulating hormones; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia areata; Pressure ulcer; Pruritus; Seborrhoeic dermatitis; Vitiligo
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Alopecia areata in USA
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Pressure-ulcer in USA
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Seborrhoeic-dermatitis in USA